To determine the clinical relevance of ODC1 and SRM expression in breast cancer, we analyzed METABRIC database and found that ODC1 and SRM expression was higher in primary tumor samples of patients who received neoadjuvant chemotherapy compared with patients who did not receive chemotherapy (Figure 2P; Table S12, Supporting Information), and in samples of patients who had metastasis within 5 years compared with patients who did not have metastasis within 5 years (Figure 2Q; Table S13, Supporting Information). Here, ODC1 is linked to breast carcinoma.